Meeting
2024 ASCO Genitourinary Cancers Symposium
Guiding adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient-derived organoids.
Authors
Martin Egger
Spitalzentrum Biel, Biel/Bienne, Switzerland
Martin Egger , Marta De Menna , Pavel Lyatoshinsky , Jennifer Blarer , Raphael Hösli , Dominik Abt , Roland Seiler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05024734
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr TPS711)
DOI
10.1200/JCO.2024.42.4_suppl.TPS711
Abstract #
TPS711
Poster Bd #
M11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Study of real-world treatment patterns and adherence to bacillus Calmette-Guerin (BCG) in the context of guideline recommendations for patients with high-risk non-muscle invasive bladder cancer (NMIBC).
First Author: Franklin D Gaylis
Poster
2020 Genitourinary Cancers Symposium
A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guérin (BCG) therapy.
First Author: Gary D. Steinberg
Poster
2020 Genitourinary Cancers Symposium
Disease progression among patients who receive available bladder preservation therapies after failure of BCG therapy in the SEER-Medicare data.
First Author: Ashish M. Kamat
Poster
2024 ASCO Quality Care Symposium
Alopecia as an uncommon side effect of single postoperative instillation of gemcitabine in patients with non-muscle-invasive urothelial carcinoma of the bladder.
First Author: Anosh Dadabhoy